2020
DOI: 10.1016/j.bbadis.2018.11.015
|View full text |Cite
|
Sign up to set email alerts
|

Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
81
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 90 publications
(90 citation statements)
references
References 139 publications
0
81
0
Order By: Relevance
“…These Cancer Stem Cells (CSCs) give rise to shorter-lived malignant cells that make up the bulk of the tumor. At the same time, they are able to sustain long-term tumor growth thanks to their self-renewal ability and their increased resistance to chemotherapy and radiotherapy [46,47]. Moreover, CSCs are thought to be primarily responsible for tumor relapse [46,47].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…These Cancer Stem Cells (CSCs) give rise to shorter-lived malignant cells that make up the bulk of the tumor. At the same time, they are able to sustain long-term tumor growth thanks to their self-renewal ability and their increased resistance to chemotherapy and radiotherapy [46,47]. Moreover, CSCs are thought to be primarily responsible for tumor relapse [46,47].…”
Section: Discussionmentioning
confidence: 99%
“…At the same time, they are able to sustain long-term tumor growth thanks to their self-renewal ability and their increased resistance to chemotherapy and radiotherapy [46,47]. Moreover, CSCs are thought to be primarily responsible for tumor relapse [46,47]. Although solid evidence supports such a hierarchical organization in many tumor types, it is not clear whether this would apply to all cancer types [48].…”
Section: Discussionmentioning
confidence: 99%
“…Notably, oncomiR‐21 can be as an activator for CAFs in TME (Nouraee et al, ). Sorafenib and sunitinib are other two FDA approved drugs to target the vascular endothelial growth factor receptors (VEGFRs) (Makena, Ranjan, Thirumala, & Reddy, ). Both the drugs reduce both tumor angiogenesis and cell proliferation at the same time because, in addition to VEGFRs, they also inhibit platelet‐derived growth factor receptors and receptor tyrosine kinase, which play a role in cell proliferation (Keating & Santoro, ).…”
Section: Targeting Ccscsmentioning
confidence: 99%
“…Notably, oncomiR-21 can be as an activator for CAFs in TME (Nouraee et al, 2013). Sorafenib and sunitinib are other two FDA approved drugs to target the vascular endothelial growth factor receptors (VEGFRs) (Makena, Ranjan, Thirumala, & Reddy, 2018).…”
Section: T a B L E 3 Targeting Ccscs' Cell Surface Moleculesmentioning
confidence: 99%
See 1 more Smart Citation